Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis
Treatment with E/T/I does not lead to changes in depression or anxiety symptoms at the population level in this single center cohort study. A prior diagnosis of depression trended towards an increased odds of worsening PHQ-9 scores after E/T/I initiation.
Authors
- Scott H. Donaldson (ORCID: https://orcid.org/0000-0003-4802-0388)
- Margret Z. Powell (ORCID: https://orcid.org/0000-0003-3681-8851)
- Jennifer L. Goralski (ORCID: https://orcid.org/0000-0002-6785-5076)
- Agathe Ceppe (ORCID: https://orcid.org/0009-0008-9031-1166)
- Nathaniel A. Sowa (ORCID: https://orcid.org/0000-0002-3021-4005)
- Harish Pudukodu (ORCID: https://orcid.org/0000-0003-3193-9427)
Institutions
- University of North Carolina at Chapel Hill (US)
- Brigham and Women's Hospital (US)
- Baylor University (US)
Publication Details
- Journal
- The Clinical Respiratory Journal
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1111/crj.70007
- Citations
- 9
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- School of Medicine, University of North Carolina at Chapel Hill